<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03025828</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 16-2402</org_study_id>
    <nct_id>NCT03025828</nct_id>
  </id_info>
  <brief_title>Adrenocorticotropic Hormone in Membranous Nephropathy</brief_title>
  <official_title>Changes in Autoreactive Memory B Cells as Biomarker of Response to Adrenocorticotropic Hormone in Patients With Membranous Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of adrenocorticotropic hormone (ACTH,
      Acthar) on the loss of proteins in the urine (proteinuria) in patients with membranous
      nephropathy. Acthar is a hormone that stimulates steroid production from small glands above
      the kidneys. It has direct protective effects on the kidney and is currently approved by the
      FDA to treat kidney disorders associated with proteins in the urine, but the mechanisms of
      action are not entirely understood and will be studied in the present trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with membranous nephropathy and nephrotic syndrome will be treated with ACTH for 6
      months. Proteinuria remission at 12 months will be the primary endpoint. Different biomarkers
      including anti-PLA2R autoantibodies, circulating regulatory T cells, and autoreactive memory
      B cells will be serially measured to identify predictors of response to therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2018</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission of proteinuria</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>Change in proteinuria at baseline versus after 12 months of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24h Proteinuria</measure>
    <time_frame>12 months</time_frame>
    <description>Protein concentration in the urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Glomerular Filtration Rate (GFR)</measure>
    <time_frame>12 months</time_frame>
    <description>GFR measures kidney function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PLA2R antibodies levels</measure>
    <time_frame>12 months</time_frame>
    <description>blood levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PLA2R memory B cells</measure>
    <time_frame>12 months</time_frame>
    <description>blood levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+CD25+CD127lowFoxP3+ T cell</measure>
    <time_frame>12 months</time_frame>
    <description>blood levels - one single cell subset identified by different markers</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Membranous Nephropathy</condition>
  <arm_group>
    <arm_group_label>Acthar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acthar will be administered subcutaneously (SC) 80 units for the first week and then 80 units twice weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACTHar</intervention_name>
    <description>for 6 months</description>
    <arm_group_label>Acthar</arm_group_label>
    <other_name>ACTH</other_name>
    <other_name>Acthar Injectable Product</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 70 years

          -  Free of immunosuppression for at least 3 months

          -  Capability of understanding the purpose of the study

          -  Written informed consent

        Exclusion Criteria:

          -  epidermal growth factor receptor (eGFR) &lt; 30ml/min/1.73m2

          -  Kidney Transplant

          -  Secondary MN (defined on the basis of clinical criteria)

          -  Type 1 or Type 2 diabetes mellitus (prior diagnosis of gestational diabetes mellitus
             is not an exclusion)

          -  History of previous use of Acthar for treatment of nephrotic syndrome

          -  Prior sensitivity to Acthar or other porcine protein products

          -  Contraindication to Acthar per Prescribing Information

          -  Planned treatment with live or live attenuated vaccines once enrolled in the study

          -  More than three previous treatment regiments

          -  Participation to other clinical trials over the previous 12 months

          -  History of cancer, except carcinoma in situ and treated basal and squamous cell
             carcinomas

          -  Pregnancy

          -  Lactation

          -  Current substance abuse

          -  Any clinically relevant condition that might affect study participation and/or study
             results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo Cravedi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paolo Cravedi, MD, PhD</last_name>
    <phone>212-241-3349</phone>
    <email>paolo.cravedi@mssm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ibeawuchi Okoroafor, MD</last_name>
    <email>ibeawuchi.okoroafor@mssm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Cravedi, MD, PhD</last_name>
      <phone>212-241-3349</phone>
      <email>paolo.cravedi@mssm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ibeawuchi Okoroafor, MD</last_name>
      <phone>212-241-2954</phone>
      <email>ibeawuchi.okoroafor@mssm.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2017</study_first_submitted>
  <study_first_submitted_qc>January 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2017</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Membranous nephropathy</keyword>
  <keyword>adrenocorticotropic hormone</keyword>
  <keyword>ACTH</keyword>
  <keyword>proteinuria</keyword>
  <keyword>glomerulonephritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
    <mesh_term>Melanocyte-Stimulating Hormones</mesh_term>
    <mesh_term>beta-Endorphin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

